Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres
Background: Immune checkpoint inhibitors (ICIs) have revolutionized the therapeutic horizons of various cancers. However, immune-related adverse events have been reported, including interstitial lung diseases. Our aim was to describe the clinical and radiological features and survival of a multicent...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/12/8/1149 |
| _version_ | 1827617812973092864 |
|---|---|
| author | Paolo Cameli Paola Faverio Katia Ferrari Viola Bonti Stefania Marsili Maria Antonietta Mazzei Francesca Mazzoni Maurizio Bartolucci Vieri Scotti Federica Bertolini Fausto Barbieri Cinzia Baldessari Chiara Veronese Roberto Boffi Matteo Brighenti Diego Cortinovis Massimo Dominici Alberto Pesci Elena Bargagli Fabrizio Luppi |
| author_facet | Paolo Cameli Paola Faverio Katia Ferrari Viola Bonti Stefania Marsili Maria Antonietta Mazzei Francesca Mazzoni Maurizio Bartolucci Vieri Scotti Federica Bertolini Fausto Barbieri Cinzia Baldessari Chiara Veronese Roberto Boffi Matteo Brighenti Diego Cortinovis Massimo Dominici Alberto Pesci Elena Bargagli Fabrizio Luppi |
| author_sort | Paolo Cameli |
| collection | DOAJ |
| description | Background: Immune checkpoint inhibitors (ICIs) have revolutionized the therapeutic horizons of various cancers. However, immune-related adverse events have been reported, including interstitial lung diseases. Our aim was to describe the clinical and radiological features and survival of a multicentre cohort of patients who developed ICI-related lung toxicity. Methods: Six Italian centres were involved in the study. Patients who were treated with anti-PD-1/PD-L1 and CTLA-4 mAbs and developed ICI-related lung toxicity were recruited retrospectively to study clinical, radiological, immunological and survival data. Results: A total of 41 patients (25 males, 66.8 ± 9.9 years) were enrolled. Lung toxicity occurred after 204.3 ± 208.3 days of therapy, with ground glass opacities being the most common HRCT pattern (23 cases). Male sex, lung cancer and acute respiratory failure were associated with a shorter latency of toxicity (<i>p</i> = 0.0030, <i>p</i> = 0.0245 and <i>p</i> = 0.0390, respectively). Patients who required high-flow oxygen therapy showed significantly worse survival (<i>p</i> = 0.0028). Conclusions: Our cohort showed heterogeneous clinical and radiological aspects of ICI-related lung toxicity, with a latency not limited to the first year of treatment. Severity was mainly mild to moderate, although life-threatening events did occur. Our data indicate that strict long-term follow-up is needed to enable early diagnosis and appropriate management. |
| first_indexed | 2024-03-09T09:54:43Z |
| format | Article |
| id | doaj.art-ceeaa02fde5741feb0c5e586c950bd99 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-09T09:54:43Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-ceeaa02fde5741feb0c5e586c950bd992023-12-01T23:54:18ZengMDPI AGLife2075-17292022-07-01128114910.3390/life12081149Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian CentresPaolo Cameli0Paola Faverio1Katia Ferrari2Viola Bonti3Stefania Marsili4Maria Antonietta Mazzei5Francesca Mazzoni6Maurizio Bartolucci7Vieri Scotti8Federica Bertolini9Fausto Barbieri10Cinzia Baldessari11Chiara Veronese12Roberto Boffi13Matteo Brighenti14Diego Cortinovis15Massimo Dominici16Alberto Pesci17Elena Bargagli18Fabrizio Luppi19Respiratory Diseases Unit, Department of Medicine, Surgery and Neurosciences, Siena University Hospital, University of Siena, 53100 Siena, ItalyRespiratory Unit, University of Milan-Bicocca, S. Gerardo Hospital, 20900 Monza, ItalyRespiratory Medicine Unit, Careggi University Hospital, 50134 Florence, ItalyRespiratory Medicine Unit, Careggi University Hospital, 50134 Florence, ItalyOncology Unit, Azienda Ospedaliera Universitaria Senese, 53100 Siena, ItalyDepartment of Medical, Surgical and Neuro Sciences, University of Siena, 53100 Siena, ItalyMedical Oncology Unit, Careggi University Hospital, 50134 Florence, ItalyRadiology Department, Careggi University Hospital, 50134 Florence, ItalyRadiation Oncology Unit, Careggi University Hospital, 50134 Florence, ItalyDivision of Medical Oncology, Modena University Hospital, 41100 Modena, ItalyDivision of Medical Oncology, Modena University Hospital, 41100 Modena, ItalyDivision of Medical Oncology, Modena University Hospital, 41100 Modena, ItalySS Lung Unit, Critical Care Medicine Department, Foundation IRCCS National Cancer Institute of Milan, 20133 Milan, ItalySS Lung Unit, Critical Care Medicine Department, Foundation IRCCS National Cancer Institute of Milan, 20133 Milan, ItalyMedical Oncology, ASST Cremona, 26100 Cremona, ItalySC Medical Oncology, SS Lung Unit, ASST H S Gerardo, 20900 Monza, ItalyDivision of Medical Oncology, Modena University Hospital, 41100 Modena, ItalyRespiratory Unit, University of Milan-Bicocca, S. Gerardo Hospital, 20900 Monza, ItalyRespiratory Diseases Unit, Department of Medicine, Surgery and Neurosciences, Siena University Hospital, University of Siena, 53100 Siena, ItalyRespiratory Unit, University of Milan-Bicocca, S. Gerardo Hospital, 20900 Monza, ItalyBackground: Immune checkpoint inhibitors (ICIs) have revolutionized the therapeutic horizons of various cancers. However, immune-related adverse events have been reported, including interstitial lung diseases. Our aim was to describe the clinical and radiological features and survival of a multicentre cohort of patients who developed ICI-related lung toxicity. Methods: Six Italian centres were involved in the study. Patients who were treated with anti-PD-1/PD-L1 and CTLA-4 mAbs and developed ICI-related lung toxicity were recruited retrospectively to study clinical, radiological, immunological and survival data. Results: A total of 41 patients (25 males, 66.8 ± 9.9 years) were enrolled. Lung toxicity occurred after 204.3 ± 208.3 days of therapy, with ground glass opacities being the most common HRCT pattern (23 cases). Male sex, lung cancer and acute respiratory failure were associated with a shorter latency of toxicity (<i>p</i> = 0.0030, <i>p</i> = 0.0245 and <i>p</i> = 0.0390, respectively). Patients who required high-flow oxygen therapy showed significantly worse survival (<i>p</i> = 0.0028). Conclusions: Our cohort showed heterogeneous clinical and radiological aspects of ICI-related lung toxicity, with a latency not limited to the first year of treatment. Severity was mainly mild to moderate, although life-threatening events did occur. Our data indicate that strict long-term follow-up is needed to enable early diagnosis and appropriate management.https://www.mdpi.com/2075-1729/12/8/1149nivolumabpulmonary fibrosisPD-1 inhibitorslung cancercheckpoint inhibitor toxicity |
| spellingShingle | Paolo Cameli Paola Faverio Katia Ferrari Viola Bonti Stefania Marsili Maria Antonietta Mazzei Francesca Mazzoni Maurizio Bartolucci Vieri Scotti Federica Bertolini Fausto Barbieri Cinzia Baldessari Chiara Veronese Roberto Boffi Matteo Brighenti Diego Cortinovis Massimo Dominici Alberto Pesci Elena Bargagli Fabrizio Luppi Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres Life nivolumab pulmonary fibrosis PD-1 inhibitors lung cancer checkpoint inhibitor toxicity |
| title | Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres |
| title_full | Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres |
| title_fullStr | Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres |
| title_full_unstemmed | Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres |
| title_short | Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres |
| title_sort | immune checkpoint inhibitor related lung toxicity a multicentre real life retrospective portrait from six italian centres |
| topic | nivolumab pulmonary fibrosis PD-1 inhibitors lung cancer checkpoint inhibitor toxicity |
| url | https://www.mdpi.com/2075-1729/12/8/1149 |
| work_keys_str_mv | AT paolocameli immunecheckpointinhibitorrelatedlungtoxicityamulticentrerealliferetrospectiveportraitfromsixitaliancentres AT paolafaverio immunecheckpointinhibitorrelatedlungtoxicityamulticentrerealliferetrospectiveportraitfromsixitaliancentres AT katiaferrari immunecheckpointinhibitorrelatedlungtoxicityamulticentrerealliferetrospectiveportraitfromsixitaliancentres AT violabonti immunecheckpointinhibitorrelatedlungtoxicityamulticentrerealliferetrospectiveportraitfromsixitaliancentres AT stefaniamarsili immunecheckpointinhibitorrelatedlungtoxicityamulticentrerealliferetrospectiveportraitfromsixitaliancentres AT mariaantoniettamazzei immunecheckpointinhibitorrelatedlungtoxicityamulticentrerealliferetrospectiveportraitfromsixitaliancentres AT francescamazzoni immunecheckpointinhibitorrelatedlungtoxicityamulticentrerealliferetrospectiveportraitfromsixitaliancentres AT mauriziobartolucci immunecheckpointinhibitorrelatedlungtoxicityamulticentrerealliferetrospectiveportraitfromsixitaliancentres AT vieriscotti immunecheckpointinhibitorrelatedlungtoxicityamulticentrerealliferetrospectiveportraitfromsixitaliancentres AT federicabertolini immunecheckpointinhibitorrelatedlungtoxicityamulticentrerealliferetrospectiveportraitfromsixitaliancentres AT faustobarbieri immunecheckpointinhibitorrelatedlungtoxicityamulticentrerealliferetrospectiveportraitfromsixitaliancentres AT cinziabaldessari immunecheckpointinhibitorrelatedlungtoxicityamulticentrerealliferetrospectiveportraitfromsixitaliancentres AT chiaraveronese immunecheckpointinhibitorrelatedlungtoxicityamulticentrerealliferetrospectiveportraitfromsixitaliancentres AT robertoboffi immunecheckpointinhibitorrelatedlungtoxicityamulticentrerealliferetrospectiveportraitfromsixitaliancentres AT matteobrighenti immunecheckpointinhibitorrelatedlungtoxicityamulticentrerealliferetrospectiveportraitfromsixitaliancentres AT diegocortinovis immunecheckpointinhibitorrelatedlungtoxicityamulticentrerealliferetrospectiveportraitfromsixitaliancentres AT massimodominici immunecheckpointinhibitorrelatedlungtoxicityamulticentrerealliferetrospectiveportraitfromsixitaliancentres AT albertopesci immunecheckpointinhibitorrelatedlungtoxicityamulticentrerealliferetrospectiveportraitfromsixitaliancentres AT elenabargagli immunecheckpointinhibitorrelatedlungtoxicityamulticentrerealliferetrospectiveportraitfromsixitaliancentres AT fabrizioluppi immunecheckpointinhibitorrelatedlungtoxicityamulticentrerealliferetrospectiveportraitfromsixitaliancentres |